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Strengths and limitations of this study
 ► This study will provide synthesised information re-
lated to outcomes of private sector provision of HIV 
treatment in low- income and middle- income coun-
tries (LMIC).
 ► This protocol adheres to Preferred Reporting Items 
for Systematic Review and Meta- Analysis Protocols 
guidelines to ensure objectivity in literature search, 
synthesis and reporting of outcomes from five 
databases.
 ► The results of this review will inform policy, practice 
and future research related to private sector provi-
sion of HIV treatment in LMIC.
 ► Anticipated potential limitations include high degree 
of heterogeneity in outcome measures (such as viral 
suppression) and settings.
 ► Exclusion of grey literature may prevent useful prac-
tical information and data being considered.
AbStrACt
Introduction Private sector provision of HIV 
treatment is increasing in low- income and middle- 
income countries (LMIC). However, there is limited 
documentation of its outcomes. This protocol reports 
a proposed systematic review that will synthesise 
clinical outcomes of private sector HIV treatment in 
LMIC.
Methods and analysis This review will be conducted 
in accordance with the preferred reporting items 
for systematic review and meta- analyses protocols. 
Primary outcomes will include: (1) proportion of eligible 
patients initiating antiretroviral therapy (ART); (2) 
proportion of those on ART with <1000 copies/mL; 
(3) rate of all- cause mortality among ART recipients. 
Secondary outcomes will include: (1) proportion 
receiving Pneumocystis jiroveci pneumonia prophylaxis; 
(2) proportion with >90% ART adherence (based on 
any measure reported); (3) proportion screened for 
non- communicable diseases (specifically cervical 
cancer, diabetes, hypertension and mental ill health); 
(iv) proportion screened for tuberculosis. A search of 
five electronic bibliographical databases (Embase, 
Medline, PsychINFO, Web of Science and CINAHL) and 
reference lists of included articles will be conducted to 
identify relevant articles reporting HIV clinical outcomes. 
Searches will be limited to LMIC. No age, publication 
date, study- design or language limits will be applied. 
Authors of relevant studies will be contacted for 
clarification. Two reviewers will independently screen 
citations and abstracts, identify full text articles for 
inclusion, extract data and appraise the quality and 
bias of included studies. Outcome data will be pooled 
to generate aggregative proportions of primary and 
secondary outcomes. Descriptive statistics and a 
narrative synthesis will be presented. Heterogeneity 
and sensitivity assessments will be conducted to aid 
interpretation of results.
Ethics and dissemination The results of this review 
will be disseminated through a peer- reviewed scientific 
manuscript and at international scientific conferences. 
Results will inform quality improvement strategies, 
replication of identified good practices, potential policy 
changes, and future research.
PrOSPErO registration number CRD42016040053.
IntrOduCtIOn
The HIV epidemic has placed a dispro-
portionate burden on health systems in 
low- income and middle- income countries 
(LMIC).1 As antiretroviral therapy (ART) is 
being scaled up, the infrastructure, informa-
tion systems, diagnostics and human resources 
required for the provision and sustained 
monitoring of HIV treatment are becoming 
increasingly inadequate in countries with 
high prevalence and incidence of HIV.2–6 
Currently, over 21.7 million people in LMIC 
are on ART,7 having risen from 1 million in 
2001.8 The number of people living with HIV 
who are immediately eligible for treatment 
has increased significantly following WHO 
guidelines for early treatment regardless of 
CD4 count.9
Rising numbers of people in need of HIV 
treatment has placed significant challenges 
and burden on health systems in LMIC. In 
response to the increasing burden on public 
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of providing ART have emerged. These include the 
deployment of community health workers to support 
community- based ART distribution,10 task- shifting of 
ART provision to nurses instead of doctors,11 spacing of 
patient appointments to reduce overcrowding at clinics 
and decentralisation of ART from congested tertiary 
facilities to local primary health centres.12 Of partic-
ular importance, however, is the proliferation of private 
sector clinics that are playing an increasing, but relatively 
nascent role in the provision of ART.13 As a result of this 
expansion, there is an evolving realisation that the private 
sector could contribute to ART provision, alleviating pres-
sure on public facilities.13
However, there has been uncertainty regarding the 
quality of ART services offered through new models of 
treatment provision.14 Although exploration of alterna-
tive ART delivery models is a necessity, short- term and 
long- term patient outcomes should not be compro-
mised.1 Evidence from several countries suggests that 
enforcement of policies and dissemination of updated 
clinical guidelines in private clinics is generally more 
difficult compared with public facilities,15 16 which 
may affect quality. User fees borne by clients accessing 
services from private practitioners could also affect 
quality for example, by contributing to missed appoint-
ments when patients lack fees.13 These concerns are 
amplified by an ongoing ideological dilemma regarding 
the extent to which the private sector should be lever-
aged to provide ART, when the primary responsibility 
of providing universal healthcare rests with govern-
ments.17 18 A large number of people in countries such 
as South Africa, India, Namibia, Papua New Guinea 
and Tanzania are accessing ART through private 
providers.19–23 Yet searches of Embase, Cochrane Library 
and PubMed databases suggest that there is limited liter-
ature describing pooled outcomes of ART delivered by 
the private sector in LMIC.
In response to this gap, this protocol documents a 
proposed systematic review, which will describe and 
synthesise the outcomes of private sector provision of ART 
in LMIC. The specific research question is: what are the 
clinical outcomes of ART from private sector in LMIC? 
This review will not compare private versus public provi-
sion of ART. The first objective will be to aggregate clinical 
outcomes of ART provision by the private sector in LMIC. 
The second objective will be to identify evidence gaps, if 
any. Depending on the findings, recommendations for 
policy, practice and future research will be made.
MEthOdS
This review will be conducted in accordance with the 
Preferred Reporting Items for Systematic Review and 
Meta- Analysis Protocols (PRISMA- P) 2015 statement,24 25 
and this protocol follows the PRISMA- P statement and 
checklist24 (see online supplementary appendix 1 for the 
checklist).
data sources
A search will be conducted to identify published peer- 
reviewed literature in the following databases: Embase, 
Medline, PsychINFO, Web of Science and CINAHL. Refer-
ence lists of included papers will be manually searched 
for additional relevant citations. Additionally, ‘cited by’ 
tool in Google Scholar will be used to identify potentially 
relevant studies. Non- peer reviewed literature will not be 
included. Authors of ongoing studies and in- press liter-
ature will be contacted for information regarding addi-
tional studies or missing data.
Search strategy
A search will be conducted by two health practitioners 
(GM and EI), who are familiar with HIV service provision 
and systematic searches, using a search strategy developed 
for searching electronic sources (see online supplemen-
tary appendix 2). This search strategy will use a combi-
nation of relevant keywords and geographical limits, the 
latter to ensure that search focusses on LMIC. No age, 
publication date or language limits will be applied. This 
search strategy will be further adapted and tailored for 
use with each database, using Boolean operators, trunca-
tions, proximity operators and Medical Subject Heading, 
as appropriate for each database.
Inclusion and exclusion criteria
 Study design
All study designs, including primary non- randomised and 
randomised controlled trials (RCTs), as well as primary 
observational studies, such as before and after, cohort, 
case–control and cross- sectional studies, will be included. 
Studies will be excluded if they are not reporting primary 
data, such as non- original research, secondary reports, 
commentaries, editorials and reviews. Qualitative, 
economic analysis and mathematical modelling studies 
will be excluded, primarily because the interest in this 
review is clinical in nature as shown in table 1.
 Domain
Studies will be included if they are related to HIV.
 Population
Studies will be included if they report data generated 
from HIV- infected participants, regardless of age, gender 
and sex.
 Intervention
The review will include studies in which participants 
are exposed to private- sector provision of ART, regard-
less of duration of exposure. For the purpose of this 
review, the definition of private sector is hinged on the 
setting in which treatment is provided, such as private 
clinics, mission hospitals and facilities, for a fee to the 
practitioners. Studies conducted in public health facili-
ties under ministries of health, will be excluded, even 
if non- governmental entities may have been involved 
in providing technical assistance. Because or defini-
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Table 1 Primary and secondary outcomes of the review
Outcome level Outcomes
Primary outcomes Proportion of eligible patients initiating ART
Proportion of those on ART with <1000 copies/mL
Rate of all- cause mortality
Secondary outcomes Proportion receiving Pneumocystis jiroveci pneumonia prophylaxis
Proportion with >90% ART adherence (based on any measure reported)
Proportion screened for non- communicable diseases (that is cervical cancer, diabetes, hypertension 
and mental health)
Proportion screened for tuberculosis
ART, antiretroviral therapy.
to private sector, it is possible that fee payment could 
be made by external entities—such as governments, on 
behalf of patients. Studies that report outcomes from 
such outsourced contracting of private sector for a fee by 
governments will be included. Studies that include both 
private and public sector will be included, but only data 
related to private sector patients will be extracted. Studies 
that report outcomes wholly from public sector, and those 
that fail to provide an adequate description of whether 
the setting was a private or public facility will be excluded. 
In addition, studies that include both private and public 
sector but fail to segregate data from these two settings 
will be excluded.
 Comparator
This review does not focus on comparison, but rather, 
pooling of outcomes from the private sector. Studies will 
be included regardless of whether they report compara-
tive outcomes from a control arms.
 Outcomes
Relevant patient- related primary outcomes are: initiation 
of ART, retention, viral suppression, all- cause mortality 
and adherence to ART.
Secondary outcomes will include indicators of quality 
of care related to opportunistic infections and non- 
communicable diseases. The denominators of these 
proportional primary and secondary outcomes will be 
the total number of patients under the care of private 
practitioners within included studies. Studies that do not 
report on any of these primary or secondary outcomes, or 
those that fail to provide an adequate description of the 
outcomes will be excluded (table 1).
 Geographical context
Studies will be included if they are conducted in LMIC, as 
defined by the World Bank (http:// data. worldbank. org/ 
country). Studies will be excluded if they report research 
that wholly took place in developed countries. In the 
event that studies report multicountry research, relevant 
data from eligible LMIC will be considered, if adequately 
disaggregated by country.
Study selection and data extraction
All citations will be imported to EndNote and dupli-
cates removed prior to screening. Studies will be inde-
pendently screened by two review team members (GM, 
EI) in two stages. Reviewers will not be blinded to journal 
or author details. In the first stage, titles and abstracts will 
be screened to exclude ineligible studies, using a broad, 
customised and pilot tested checklist for study selection 
(see online supplementary appendix 3). In the second 
stage, full text versions of selected abstracts will be down-
loaded/retrieved and assessed independently by the 
two reviewers to ensure that inclusion criteria are met. 
Screening and selection of studies will be facilitated by the 
creation of appropriately labelled subfolders in EndNote, 
to segregate studies for inclusion and exclusion.
At each stage, selected papers will be compared between 
the two reviewers for concordance. In the event of uncer-
tainty or disagreement, the two authors will confer and 
discuss with each other and, if necessary, a third review 
author (GWM) to reach consensus. Where separate 
papers report data from the same cohort, these data will 
be reported as one study and only data from the most 
recent paper with the longest duration of follow- up will 
be extracted to limit bias arising from multiple reporting 
of data from same participants.26 27 When abstracts and 
subsequent included papers are not available in English, 
translators will be sought. In accordance with PRISMA- P 
guidelines for a systematic review,24 a flow diagram illus-
trating the literature search, article selection and final 
included studies will be generated.
data extraction
A standard data extraction form will be constructed for 
this review in Microsoft Word and piloted on at least three 
random studies selected from an initial list of included 
studies. Based on the pilot, the data extraction form will 
be modified as necessary. Data will be extracted by two 
authors working independently (GM and EI). Once all 
data are extracted, a ‘Characteristics of Included Studies’ 
table will be created using methods suggested by the 
Cochrane Handbook for Systematic Reviews of Interven-
tions to summarise the included studies.28 Extracted infor-
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Table 2 Types of data to be extracted
Field Description
Author First author
Multiple papers reporting on the same participants are treated as one study
Year Year the study was published
Country of study Country in which the study was conducted
For multicountry studies, only data related to low- income or middle- income countries will be 
extracted
Design Description of study design and research methodology
Setting Site of study (community, health facility, etc), patient recruitment and conduct of the study
Study population Study population characteristics (age, sex, sexual identity or other characteristics)
Intervention Description of ART- related clinical services provided by healthcare providers in different 
countries including timing and duration
Primary outcomes Summary of primary outcomes assessed
Where reported, proportions, rates or other measures of risks, as well as HR and confidence 
limits will be included
Calculated outcomes will be marked as ‘calculated’
Secondary outcomes Summary of secondary outcomes assessed
Where reported, proportions, rates or other measures of risks, as well as HR and confidence 
limits will be included
Calculated outcomes will be marked as ‘calculated’
Quality assessment Quality scores of included studies
Limitations Sources of bias
ART, antiretroviral therapy; HR, hazard ratio.
study design, research methodology, country in which 
the study was conducted, participants’ characteristics and 
recruitment, intervention type and duration, primary and 
secondary outcomes with point estimates and confidence 
limits, and study limitations (table 2).
Extracted data will be compared between the two 
reviewers for each included study. Discrepancies will be 
documented and resolved via review of the full text of 
manuscripts, discussion and consensus between the two 
reviewers. Data assumed to be missing at random may not 
be important and will be ignored, however, one attempt 
will be made to contact, by email, the corresponding 
authors of studies containing data not assumed to be 
missing at random. If the authors provide no additional 
information, the two reviewers will make a decision as to 
whether to include the study in the final review. Once 
all data are extracted, a table will be used to provide a 
summary overview of the included articles’ characteristics.
Quality and bias assessment
Two review authors (GM, EI) will evaluate the risk of 
different types of biases, including selection bias, inter-
vention performance bias, attrition bias, detection bias 
and reporting bias using the Cochrane Collaboration’s 
tool for assessing risk of bias.28 In addition, assessment of 
methodological quality will be conducted using Newcastle- 
Ottawa Quality Assessment Scale, which is a validated tool 
for assessing quantitative cross sectional, case–control 
and cohort studies.29 Scores between 7 and the maximum 
score of 9 will be defined as high quality, scores between 
4 and 6 will be defined as intermediate quality and scores 
between 1 and 3 will be defined as low quality. We do not 
anticipate to find eligible RCTs, and as stated earlier in 
this protocol, qualitative studies will be excluded. Two 
authors, GM and EI will conduct risk and quality assess-
ments and will score each study independently.Discrepan-
cies in scoring will be resolved by discussion with a third 
author (GWM). Studies will be included regardless of risk 
of bias and quality scores, but sensitivity analysis will be 
conducted to ascertain the impact of their inclusion.
data synthesis and presentation
All available quantitative data will be pooled for each 
outcome using STATA version 16, SPSS version 23 or 
RevMan. For dichotomous outcomes, we will analyse and 
pool and aggregate data related to proportions of having 
the outcome of interest and 95% CIs using a random 
effect model. For continuous outcomes, we will pool data 
based on the arithmetic means (or medians). To aggregate 
quantitative outcomes, meta- analysis will be conducted if 
at least five studies providing data regarding any primary 
outcome are identified for inclusion, unless the data are 
substantially heterogeneous statistically. If there is insuf-
ficient data for aggregative pooling, that is, less than five 
studies reporting same primary outcomes, the results will 
be presented in a narrative format. However, a final deci-
sion will be made once available data have been obtained 
and systematically appraised.
Some heterogeneity is anticipated and could be related 
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measures, types of patients and reported effects. To assess 
if variability in outcomes will be due to chance or true 
heterogeneity, χ2 test for heterogeneity will be conducted 
for each outcome, and the results quantified using I2 
statistic. An I2 value greater than 50% will be considered 
an indicator of substantial heterogeneity.28 In these cases, 
pooled results from the meta- analysis will not be reported; 
rather, a narrative approach will be utilised to report the 
findings. If sufficient (at least five, homogeneous) studies 
are identified, subgroup analysis will be conducted based 
on age (adult vs children <10 years old) and sex.
The authors will make one attempt to contact, by email, 
the corresponding authors of studies with missing data, 
unless such data are assumed to be of limited impact on 
the findings. If corresponding authors provide no addi-
tional information within 4 weeks, GM and EI will deter-
mine whether to include the study in the final review. 
Where possible, we will compute point estimates, such as 
risk ratios, 95% CIs and p values, based on intention- to- 
treat analysis. Assumptions (eg, those related to computed 
values) will be reported. Using sensitivity analyses, effects 
of any arbitrary decisions and calculated values on pooled 
proportions will be assessed by comparing the estimated 
proportions with and without these data.
Before carefully deriving conclusions and recommen-
dations, the overall limitations of the review itself will be 
considered. Given the high volume of synthesised infor-
mation, supplementary materials will be provided online 
in formats suitable for abstracts, manuscripts and Power-
Point presentations.
Protocol registration and deviations
This protocol is registered in PROSPERO (http://www. 
crd. york. ac. uk/ PROSPERO/) to prevent duplication, 
limit reporting bias and strengthen transparency.30 The 
review commenced in 2019 is expected to be completed 
in 2020. To further limit reporting bias, and strengthen 
transparency, deviations from this protocol will be 
disclosed and discussed in the final published review.
Ethics and dissemination
The results of this review will be disseminated through 
publication in a peer- reviewed scientific manuscript and 
at international scientific conferences. Short summaries 
of the review will be disseminated through mass emails 
and social media, as these methods are often effective.31 32 
Workshop and symposium presentations will be utilised 
selectively based on audience.33
Patient and public involvement
Although involvement of patients is an important ethical 
element of research, patients were not involved in the 
development of this systematic review protocol.
dISCuSSIOn
Faced with overburdened public health systems, there is 
an increasing interest in the role that private providers 
could play in the delivery of ART in LMIC. Evidence 
suggests that a large number of people in countries 
such as South Africa, India, Namibia, Papua New 
Guinea and Tanzania are accessing ART through private 
providers.19–23 However, the concept of private providers 
in healthcare is not new, nor is it confined to ART. The 
role of the private sector in the provision of immunisation, 
family planning and other primary healthcare services in 
LMIC has been a focus of past and contemporary liter-
ature,34 35 and there is growing consensus that private 
healthcare systems have unique advantages over public 
health sectors, such as convenience.18 35 However, there is 
conflicting evidence regarding the extent to which private 
practitioners provide acceptable quality of care, are effi-
cient, and adhere to clinical guidelines.17 18 36 Although 
these concerns and contentions are neither new nor 
restricted to HIV services, they are particularly significant 
in the context of HIV, due to the large scale and lifelong 
nature of ART, hence the need for a systematic review. 
Given that private sector in LMIC is often poorly regu-
lated compared with public sector,15 16 understanding 
outcomes of ART care is an essential first step towards 
improvement of quality. If outcomes from this review are 
markedly poor for example, such results would create an 
impetus for strengthening supervision and enforcement 
of quality assurance policies in the private sector.
Limitations
Overall, it is anticipated that the review will contain a high 
degree of heterogeneity. Thresholds for some outcomes, 
such as viral suppression may be defined differently 
in different studies. In addition, the definition of what 
constitutes private sector is not always straightforward 
and may involve subjective judgement, for example, in 
relation to contracted services on behalf of governments, 
or insurance- mediated payments. Although a thorough 
search strategy has been defined, it is still possible to miss 
some studies. Exclusion of grey literature may also prevent 
useful practical information and data being consid-
ered. It is possible that many private practitioners may 
not have reported their patient care outcomes in scien-
tific papers. The scope of our review focusses on clinical 
outcomes. Although understanding the economic and 
other outcomes related to private sector provision of ART 
would be important, our study is primarily concerned 
with clinical results. Future reviews could explore cost- 
related outcomes.
Implications
Despite these possible limitations, this review will inform 
quality improvement strategies, and identify good prac-
tices for potential replication. It will provide a context 
for potential policy changes and future research. It will 
be useful to policy makers, public health authorities and 
national HIV programmes in LMIC as they seek to find 
alternative models of ART provision that could comple-
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